With two debuts and a SPAC, biopharma notches another busy week as IPO raise soars past $7B
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
After a slight lull in the IPO market earlier this month, the industry returned in full force this week by celebrating two new Nasdaq entrants in addition to a SPAC merger.
Centessa comes in as the biggest winner, pulling in a $330 million haul and pricing above its expected range at $20 per share Friday. The 10-in-1 holding company marks the fourth-largest IPO raise among biotechs in 2021, coming ahead of all debutants except for Sana, Zymergen and Recursion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.